Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5088-5095

  Crowther Gibson, Penny ^a   Cohen, Cheryl ^a,b   Klugman, Keith P ^a,c,d   De Gouveia, Linda ^a   Von Gottberg, Anne ^a,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; OFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; RIFAMPICIN; TETRACYCLINE; TUBERCULOSTATIC AGENT;

ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD; CEREBROSPINAL FLUID; DISEASE SURVEILLANCE; DISK DIFFUSION; EPSILOMETER TEST; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PLEURA FLUID; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTYPING; SOUTH AFRICA; SYNOVIAL FLUID; URBAN AREA; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; RISK FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84866323989     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06463-11     Document Type: Article

References (58)

1. Actuarial Society of South Africa. 2011. Results extracted from the ASSA2008 AIDS and demographic model. Actuarial Society of South Africa, Cape Town, South Africa. http://aids.actuarialsociety.org.za/ASSA2008-Model-3480.htm.
2. Andersson DI. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9:461-465. (Pubitemid 44397630)
3. Appelbaum PC, et al. 1977. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet ii:995-997. (Pubitemid 8215383)
4. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR. 1994. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835. (Pubitemid 24169696)
5. Buie KA, et al. 2004. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and uninfected adults with pneumococcal bacteremia. J. Infect. Dis. 189:1996-2000. (Pubitemid 38692278)
6. Catalan MJ, et al. 1994. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin. Infect. Dis. 18:766-769. (Pubitemid 24145912)
7. Clavo-Sánchez AJ, et al. 1997. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin. Infect. Dis. 24:1052-1059.
8. CLSI. 2009. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Crewe-Brown HH, et al. 1997. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin. Infect. Dis. 25:1165-1172. (Pubitemid 27513205)
10. Dias R, Louro D, Caniça M. 2006. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period. Antimicrob. Agents Chemother. 50:2098-2105. (Pubitemid 43807531)
11. Doern GV, Brueggemann AB, Holley HP, Rauch AM. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
12. Dowell SF, Schwartz B. 1997. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am. Fam. Physician 55:1647-1654. (Pubitemid 27175506)
13. Farrell DJ, Klugman KP, Pichichero M. 2007. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 26:123-128. (Pubitemid 46183361)
14. Felmingham D. 2004. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 50:3-10. (Pubitemid 39179214)
15. French N, et al. 2010. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 362:812-822.
16. Friedland IR, Klugman KP. 1992. Antibiotic-resistant pneumococcal disease in South African children. Am. J. Dis. Child. 146:920-923.
17. Friedland IR, Klugman KP. 1992. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 339:405-408.
18. Goldstein FW. 1999. Penicillin-resistant Streptococcus pneumoniae: selection by both β-lactam and non-β-lactam antibiotics. J. Antimicrob. Chemother. 44:141-144. (Pubitemid 29389275)
19. Hampton LM, et al. 2012. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J. Infect. Dis. 205:401-411.
20. Hansman D, Bullen MM. 1967. A resistant pneumococcus. Lancet ii: 264-265.
21. Hsu HE, et al. 2009. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med. 360:244-256.
22. Huebner RE, Wasas A, Klugman KP. 2000. Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int. J. Infect. Dis. 4:214-218. (Pubitemid 32110098)
23. Jacobs MR, et al. 1978. Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299:735-740. (Pubitemid 9040908)
24. Janoff EN, Breiman RF, Daley CL, Hopewell PC. 1992. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann. Intern. Med. 117:314-324.
25. Jones N, Huebner R, Khoosal M, Crewe-Brown HH, Klugman KP. 1998. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 12:2177-2184. (Pubitemid 28495272)
26. Kaplan SL, Mason EO. 1998. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11:628-644. (Pubitemid 28497566)
27. Katsarolis I, et al. 2009. Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece. BMC Infect. Dis. 9:120-129.
28. Klugman KP. 1990. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:171-196.
29. Klugman KP. 2001. Antibiotic selection of multiply resistant pneumococci. Clin. Infect. Dis. 33:489-491. (Pubitemid 32709581)
30. Klugman KP. 2007. Risk factors for antibiotic resistance in Streptococcus pneumoniae. S. Afr. Med. J. 97:1129-1132. (Pubitemid 350285958)
31. Klugman KP, Koornhof HJ. 1988. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J. Infect. Dis. 158:956-964. (Pubitemid 18266044)
32. Klugman KP, et al. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348. (Pubitemid 37186212)
33. Koornhof HJ, Wasas A, Klugman KP. 1992. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin. Infect. Dis. 15:84-94.
34. Kristinsson KG, Hjalmarsdottir MA, Gudnason TH. 1998. Continued decline in the incidence of penicillin non-susceptible pneumococci in Iceland, abstr C-22. Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother. ASM Press, Washington, DC.
35. Kyaw MH, et al. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463.
36. Levin BR. 2002. Models for the spread of resistant pathogens. Neth. J. Med. 60:58-66.
37. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. 2000. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin. Infect. Dis. 31:170-176. (Pubitemid 32268959)
38. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. 2000. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr. Infect. Dis. J. 19:1141-1147. (Pubitemid 32003356)
39. McGee L, et al. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J. Clin. Microbiol. 39:2565-2571. (Pubitemid 32606233)
40. Mera R, Miller LA, Fritsche TR, Jones RN. 2008. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 14:101-107.
41. Mera RM, Miller LA, Daniels JJD, Weil JG, White AR. 2005. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn. Microbiol. Infect. Dis. 51:195-200. (Pubitemid 40568764)
42. Messina AF, et al. 2007. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26:461-467. (Pubitemid 46847303)
43. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. 2011. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29:9127-9131.
44. Nunes MC, et al. 2011. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 25:453-462.
45. O'Brien KL, et al. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
46. Schrag SJ, et al. 2004. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob. Agents Chemother. 48:3016-3023. (Pubitemid 38989169)
47. Schrag SJ, et al. 2001. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286:49-56. (Pubitemid 32606331)
48. Seppälä H, et al. 1997. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337:441-446. (Pubitemid 27333044)
49. Silva RF, et al. 2011. Pervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutations. PLoS Genet. 7:e1002181. doi:10.1371/journal.pgen.1002181.
50. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. 2007. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369:389-396. (Pubitemid 46177227)
51. Statistics South Africa. 2010. Results extracted from mid-year population estimates by province, gender, age group, and year 2008. Statistics South Africa, Pretoria, South Africa.
52. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. 2007. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob. Agents Chemother. 51:3491-3497. (Pubitemid 47519334)
53. von Gottberg A, et al. 2008. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 371:1108-1113.
54. Whitney CG, et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746. (Pubitemid 36514704)
55. Whitney CG, et al. 2000. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924. (Pubitemid 32064785)
56. Wolter N, du Plessis M, von Gottberg A, de Gouveia L, Klugman KP. 2009. Molecular characterization of emerging levofloxacin-nonsusceptible pneumococci in children in South Africa. J. Clin. Microbiol. 47:1319-1324.
57. Woolfson A, et al. 1997. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull. World Health Organ. 75:453-462. (Pubitemid 28037401)
58. World Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.